Journal of Contemporary Brachytherapy
eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Share:
Send email
Share:
Original paper

Chemoradiotherapy for anal canal cancers: Does the choice of boost technique matter?

Leonel Varela Cagetti
1
,
Julia Gilhodes
2
,
Marjorie Ferré
3
,
Marguerite Tyran
1
,
Morgan Guenole
1
,
Jean Philippe Ratone
4
,
Fabrice Caillol
4
,
Flora Poizat
5
,
Bernard Lelong
6
,
Cecile De Chaisemartin
6
,
Hélène Meillat
6
,
Christelle De la Fouchardière
7
,
Naji Salem
1
,
Agnès Tallet
1

  1. Department of Radiation Oncology, Institut Paoli-Calmettes, Marseille, France
  2. Department of Clinical Research and Investigation, Biostatistics and Methodology Unit, Institut Paoli-Calmettes, Aix Marseille Université, INSERM, IRD, SESSTIM, Marseille, France
  3. Department of Medical Physics, Institut Paoli-Calmettes, Marseille, France
  4. Oncology and Endoscopic Unit, Institut Paoli-Calmettes, Marseille, France
  5. Department of Pathology, Institut Paoli-Calmettes, Marseille, France
  6. Department of Digestive Surgical Oncology, Institut Paoli-Calmettes, Marseille, France
  7. Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
J Contemp Brachytherapy 2026
DOI: https://doi.org/10.5114/jcb.2026.160422
Online publish date: 2026/03/27
Article file
- Chemo-radiotherapy for.pdf  [0.39 MB]
Get citation
 
 
1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. Cancer J Clin 2008; 58: 71-96.
2. Ferlay J, Laversanne M, Ervik M et al. Global Cancer Observatory: Cancer Tomorrow (version 1.1). International Agency for Research on Cancer, Lyon, France. Available from: ttps://gco.iarc.who.int/tomorrow
3. Nigro N, Vaitrevicius V, Buroker T et al. Combined therapy for cancer of the anal canal. Dis Colon Rectum 1981; 24: 73-75.
4. Badakhshi HBadakhshi H, Budach V, Wust P et al. Anal carcinoma: surgery does not influence prognosis when performed prior to concurrent radiochemotherapy. Anticancer Res.Anticancer Res 2013; 33: 4111-4115.
5. Ortholan C, Ramaioli A, Peiffert D et al. Anal canal carcinoma: Early-stage tumors < or = 10 mm (T1 or Tis): Therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62: 479-485.
6. Ajani J, Winter K, Gunderson L et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal. A randomized controlled trial. JAMA 2008; 299: 1914-1921.
7. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348: 1049-1054.
8. Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-2049.
9. Flam M, John M, Pajak TF et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14: 2527-2539.
10. James R, Glynne-Jones R, Meadows H et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol 2013; 14: 516-524.
11. Gunderson LL, Winter KA, Ajani JA et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012; 30: 4344-4351.
12. Northover J, Glynne-Jones R, Sebag-Montefiore D et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomized UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010; 102: 1123-1128.
13. Bentzen A, Guren M, Vonen B et al. Faecal incontinence after chemoradiotherapy in anal cancer survivors: Long-term results of a national cohort. Radiother Oncol 2013; 108: 55-60.
14. Shinde A, Li R, Amini A et al. Resident experience in brachytherapy: An analysis of Accreditation Council for Graduate Medical Education case logs for intracavitary and interstitial brachytherapy from 2007 to 2018. Brachytherapy 2020; 6: 718-724.
15. Glynne-Jones R, Nilsson PJ, Aschele C et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2014; 40: 1165-1176.
16. Papillon J, Montbarbon JF, Gerard JP et al. Interstitial curietherapy in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol Biol Phys 1989; 17: 1161-1169.
17. Gerbaulet A, Potter R, Meertens H et al. The GEC ESTRO Handbook of Brachytherapy. ESTRO, Brussels, Belgium 2002; 23: 505-514.
18. Pierquin B, Dutreix A, Paine CH et al. The Paris system in interstitial radiation therapy. Acta Radiol Oncol Radiat Phys Biol 1978; 17: 33-48.
19. Lee SP, Leu MY, Smathers JB et al. Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. Int J Radiat Oncol Biol Phys 1995; 33: 375-389.
20. Nag S, Gupta N. A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys 2000; 46: 507-513.
21. Das P, Cantor SB, Parker CL et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 2010; 116: 822-829.
22. Fakhrian K, Sauer T, Dinkel A et al. Chronic adverse events and quality of life after radiochemotherapy in anal cancer patients. A single institution experience and review of the literature. Strahlenther Onkol 2013; 189: 486-494.
23. Putta S, Andreyev H. Faecal incontinence: A late side-effect of pelvic radiotherapy. Clin Oncol 2005; 17: 469-477.
24. Bruheim K, Guren MG, Skovlund E et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 1005-1011.
25. Oehler-Jänne C, Seifert B, Lütolf UM et al. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 2007; 6: 218-226.
26. Vaizey CJ, Carapeti E, Cahill JA et al. Prospective comparison of faecal incontinence grading systems. Gut 1999; 44: 77-80.
27. Bonetti L, Domati F, Farinetti A et al. Radiotherapy-induced mesorectum alterations: histological evaluation of 90 consecutive cases. Scand J Gastroenterol 2015; 50: 197-203.
28. Varela Cagetti L, Moureau-Zabotto L, Zemmour C et al. The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments. Brachytherapy 2023; 22: 531-541.
29. Haugnes HS, Melby B, Larsen KM et al. Assessment of late urinary, bowel and sexual function after dose escalation from 70 to 76 Gy using image-guided radiotherapy in curative treatment of prostate cancer. Scand J Urol Nephrol 2012; 46: 124-132.
30. Dunberger G, Lind H, Steineck G et al. Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls. Eur J Cancer 2010; 46: 606-615.
31. Pötter R, Tanderup K, Schmid M et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): A multicentre prospective cohort study. Lancet Oncol 2021; 22: 538-547.
32. Peeters ST, Hoogeman MS, Heemsbergen WD et al. Rectal bleeding,fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys 2006; 166: 11-19.
33. Lind H, Alevronta E, Steineck G et al. Defecation into clothing without forewarning and mean radiation dose to bowel and anal-sphincter among gynecological cancer survivors. Acta Oncol 2016; 55: 1285-1293.
34. Nelson R, Norton N, Cautley E et al. Community-based prevalence of anal incontinence. JAMA 1995; 274: 559-561.
35. Whitehead WE, Borrud L, Goode PS et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology 2009; 137: 512-517.
36. Campisi MC, Lancellotta V, Fionda B et al. A systematic review on the role of interventional radiotherapy for treatment of anal squamous cell cancer: multimodal and multidisciplinary therapeutic approach. Radiol Med 2024; 129: 1739-1750.
37. Kent C, Bessell EM, Scholefield JH et al. Chemoradiotherapy with brachytherapy or electron therapy boost for locally advanced squamous cell carcinoma of the anus-reducing the colostomy rate. J Gastrointest Cancer 2017; 48: 1-7.
38. Allal A, Kurtz JM, Pipard G et al. Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison. Int J Radiat Oncol Biol Phys 1993; 27: 59-66.
39. Peiffert D, Bey P, Pernot M et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: Prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys 1997; 37: 313-324.
40. Chapet O, Gerard JP, Riche B et al. Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1316-1324.
41. Tournier-Rangeard L, Peiffert D, Lafond C et al. Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation. Cancer Radiother 2007; 11: 169-177.
42. Varela Cagetti L, Zemmour C, Salem N et al. High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers. Brachytherapy 2019; 18: 814-822.
43. Lestrade L, De Bari B, Pommier P et al. Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series. Strahlenther Onkol 2014; 190: 546-554.
44. Arcelli A, Buwenge M, Macchia G et al. Long-term results of chemoradiation plus pulsed dose-rate brachytherapy boost in anal canal carcinoma: a mono-institutional retrospective analysis. J Contemp Brachytherapy 2019; 11: 21-27.
45. Bourdais R, Achkar S, Espenel S et al. Pulse-dose-rate interstitial brachytherapy in anal squamous cell carcinoma: clinical outcomes and patients’ health quality perception. J Contemp Brachytherapy 2021; 13: 263-272.
46. Doniec JM, Schniewind B, Kovács G et al. Multimodal therapy of anal cancer added by new endosonographic guided brachytherapy. Surg Endosc 2006; 20: 673-678.
47. Oehler-Jänne C, Seifert B, Lütolf UM et al. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 2007; 6: 218-226.
48. Bertin E, Benezery K, Kee DLC et al. Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal. J Contemp Brachytherapy 2018; 10: 522-531.
49. Ali ZS, Solomon E, Mann P et al. High dose rate brachytherapy in the management of anal cancer: A review. Radiother Oncol 2022; 171: 43-52.
50. Varela Cagetti L, Moureau-Zabotto L, Zemmour C et al. The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments. Brachytherapy 2023; 22: 531-541.
51. Moureau-Zabotto L, Ortholan C, Hannoun-Levi JM et al. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study). Int J Radiat Oncol Biol Phys 2013; 85: 135-142.
52. Weber DC, Kurtz JM, Allal AS et al. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2001; 50: 675-680.
53. Allal AS, Mermillod B, Roth AD et al. The impact of treatment factors on local control in T2-T3 anal carcinomas treated by radiotherapy with or without chemotherapy. Cancer 1997; 79: 2329-2335.
54. Kachnic LA, Winter K, Myerson RJ et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013; 86: 27-33.
55. Mitra D, Hong TS, Horick N et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose painted IMRT per RTOG 0529. Adv Radiat Oncol 2017; 2: 110-117.
56. Isrctn.com. PLATO – Personalising anal cancer radiotherapy dose. Available at https://doi.org/10.1186/ISRCTN-88455282.
57. Florescu C, Lequesne J, Grellard JM et al. Interim analysis of a phase II study of simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) in combination with 5-FU and mitomycin-C among patients with locally advanced anal canal cancer. J Clin Oncol 2021; 15 suppl.
58. Peiffert D, Tournier-Rangeard L, Gérard J et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03 Trial. J Clin Oncol 2012; 30: 1941-1948.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.